Core Insights - Alpha Teknova, Inc. reported a total revenue of $40.5 million for the full year 2025, representing a 7% increase year-over-year and aligning with guidance [1][7] - The company anticipates revenue for 2026 to be between $42 million and $44 million [1][16] Financial Performance - Fourth quarter 2025 total revenue was $10.0 million, an 8% increase from $9.3 million in the same quarter of 2024 [1][5] - Lab Essentials revenue for the fourth quarter was $6.8 million, consistent with the previous year, while Clinical Solutions revenue increased by 47% to $2.7 million [5][11] - Full year 2025 gross profit was $13.4 million, up from $7.2 million in 2024, with a gross margin of 33.2% compared to 19.2% in 2024 [12][14] Operating Expenses and Cash Flow - Operating expenses for 2025 were $30.4 million, down from $33.4 million in 2024, reflecting reduced spending in various areas [13] - Free Cash Flow for 2025 was negative $9.8 million, an improvement from negative $13.5 million in 2024 [15][34] - Cash used in operating activities for the full year 2025 was $8.6 million, a decrease from $12.4 million in 2024 [15] Future Outlook - The company aims to achieve Adjusted EBITDA positivity by the end of 2027, supported by increased investments in commercial capabilities [2] - Free Cash Outflow for 2026 is expected to be less than $10 million [2][16] Customer Growth - The number of Clinical Solutions customers grew by 25% in 2025 [7]

Core Viewpoint - Alpha Teknova, Inc. will report its financial results for Q4 and the full year ended December 31, 2025, on February 26, 2026, after market close [1]. Group 1: Financial Reporting - The financial results announcement is scheduled for February 26, 2026, at the close of market [1]. - A webcast and conference call will be held on the same day at 5:30 p.m. Eastern Time for investors to access the results [2]. Group 2: Company Overview - Teknova has been innovating in the manufacture of critical reagents since 1996, supporting the life sciences industry [3]. - The company offers customizable solutions for various stages of the workflow, aiding in molecular diagnostics, synthetic biology, and emerging therapeutic modalities [3]. - Teknova operates from a 180,000 square feet facility in Hollister, California, designed for efficient production of foundational ingredients for next-generation therapies [3].

Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for the second quarter of 2025 on August 7, 2025, after market close, highlighting its ongoing role in the life sciences industry as a producer of critical reagents for novel therapies and diagnostics [1]. Group 1 - Teknova will host a webcast and conference call on August 7, 2025, at 5 p.m. Eastern Time, providing access through its Investor Relations section [2]. - The webcast will be available for replay on the company's website approximately two hours after the event [2]. Group 2 - Founded in 1996, Teknova specializes in manufacturing critical reagents for the life sciences sector, aiming to accelerate the discovery and development of new therapies [3]. - The company offers customizable solutions for various stages of the workflow, supporting sectors such as molecular diagnostics and synthetic biology [3]. - Teknova operates from a 180,000 square feet facility in Hollister, California, utilizing a modular manufacturing platform designed by experts to produce foundational ingredients for next-generation therapies [3].